Press Releases
AtriCure to Participate at Upcoming Investor Conferences
July 21, 2023
MASON, Ohio --(BUSINESS WIRE)--Jul. 21, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure to Announce Second Quarter 2023 Financial Results
July 03, 2023
MASON, Ohio --(BUSINESS WIRE)--Jul. 3, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter...
AtriCure Reports First Quarter 2023 Financial Results
May 02, 2023
Worldwide revenue of $93.5 million – an increase of 25.4% year over year U.S. revenue of $78.2 million – an increase of 25.6% year over year International revenue of $15.3 million – an increase of 24.4% year over year Net loss of $6.5 million – an improvement of $8.7 million year over year Positive...
AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast
April 19, 2023
MASON, Ohio --(BUSINESS WIRE)--Apr. 19, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company will be hosting an...
AtriCure to Announce First Quarter 2023 Financial Results
April 11, 2023
MASON, Ohio --(BUSINESS WIRE)--Apr. 11, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release first quarter...
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
April 03, 2023
MASON, Ohio --(BUSINESS WIRE)--Apr. 3, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating...
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
February 21, 2023
2022 Worldwide revenue of $330.4 million – an increase of 20.4% year over year 2022 U.S. revenue of $277.2 million – an increase of 21.0% year over year 2022 International revenue of $53.2 million – an increase of 17.7% in 2022 MASON, Ohio --(BUSINESS WIRE)--Feb. 21, 2023-- AtriCure, Inc....
AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference
February 17, 2023
MASON, Ohio --(BUSINESS WIRE)--Feb. 17, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the...
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
January 31, 2023
Trial will evaluate the safety and effectiveness of the AtriCure AtriClip ® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients MASON, Ohio --(BUSINESS WIRE)--Jan. 31, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and...
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
January 24, 2023
MASON, Ohio --(BUSINESS WIRE)--Jan. 24, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth...